ArticleNature communications2026
Dissecting origin factors of lymph node metastasis in non-small cell lung cancer via multimodal omics.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dissecting origin factors of lymph node metastasis in non-small cell lung cancer via multimodal omics.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Cancer metastasis accounts for the majority of cancer-related deaths and lymph node metastasis is critical in cancer staging and prognosis. However, the mechanisms involved in lymph node metastatic non-small cell lung cancer (NSCLC) remain unclear. Here, we delineate the cellular and spatial landscape of metastatic lymph nodes and their matched primary tumors in NSCLC using multimodal omics. In results, tumor core and peripheral regions respectively exhibit high stemness and elevated expression of immunoglobulins. Increased expressions of CD274 (PD-L1) are observed in the immunoglobulin-high malignant cells and SPP1+IFI30+ macrophages. Notably, residual and tertiary lymphoid structures are identified. However, their anti-tumor immunity is compromised by CXCL13+ T cell exhaustion and immune exclusion. Furthermore, we identify the ferroptosis signaling, with its key factor FTH1 showing strong associations with cancer cell stemness and metastasis. This study elucidates the mechanisms of metastasis and immune evasion in lymph node metastatic NSCLC, providing insights for targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.